ArticleMedicine2026
An immunohistochemical diagnostic panel for Xp11.2 translocation renal cell carcinoma: A diagnostic accuracy study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcription factor binding to IGHM enhancer 3 (TFE3) break-apart fluorescence in situ hybridization (FISH) is the gold standard for the diagnosis of Xp11.2 translocation renal cell carcinoma (tRCC). However, FISH is costly and not accessible in all laboratories. We aimed to develop a surrogate immunohistochemical panel to recognize Xp11.2 tRCC. We retrospectively enrolled 84 patients who underwent surgery for renal lesions from September 2017 to August 2022. Both immunohistochemistry and FISH analysis were performed on their specimens. The sensitivity, specificity, and accuracy of each immunohistochemical marker and combinatorial immunohistochemical panels were calculated. A total of 17 patients were diagnosed with Xp11.2 tRCC using FISH. In patients with Xp11.2 tRCC, 77% (13/17), 100% (17/17), 88% (15/17), 88% (15/17), 100% (17/17), and 71% (12/17) were tested positive for AE1/AE3, CD10, P504S, PAX8, TFE3, and vimentin, respectively, while 94% (16/17) were tested negative for cytokeratin 7 (CK7). The immunohistochemical panel combining negative CK7, positive CD10, positive P504S, and positive TFE3 exhibited a sensitivity of 0.824, a specificity of 0.672, and a highest accuracy of 0.702. The immunohistochemical panel combining negative CK7, positive CD10, positive P504S, and positive TFE3 was a potentially useful tool for the diagnosis of Xp11.2 tRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.